PTK2 and neoplasm: Focal adhesion kinase (FAK) inhibitors have demonstrated reasonable anti-tumor activity in the preclinical setting. A maximal synergetic effect was achieved when a FAK inhibitor was given in combination with a PD-1 antagonist and chemotherapy in multiple pancreas tumor animal models. This supports the concept of using FAK inhibitors to reduce stromal fibrosis during checkpoint immunotherapeutic treatment. Therefore, these robust preclinical findings will be tested in the proposed phase I trial.